PubRank

G Kemball-Cook

Author PubWeight™ 28.51‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Contact activation in shock caused by invasive group A Streptococcus pyogenes. Crit Care Med 2000 1.60
2 Assay discrepancies with highly purified factor VIII concentrates. Haemostasis 1989 1.41
3 Postinjury vascular intimal hyperplasia in mice is completely inhibited by CD34+ bone marrow-derived progenitor cells expressing membrane-tethered anticoagulant fusion proteins. J Thromb Haemost 2006 1.41
4 A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 1997 1.37
5 An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. J Thromb Haemost 2013 1.28
6 The haemophilia A mutation search test and resource site, home page of the factor VIII mutation database: HAMSTeRS. Nucleic Acids Res 1996 1.25
7 Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX. Gene Ther 2006 1.10
8 Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood 2001 1.04
9 High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997 1.02
10 Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity. Thromb Haemost 1995 0.99
11 Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Demonstration of defective tissue factor binding in a variant FVII molecule (FVII-R79Q). Biochemistry 1994 0.98
12 Anticoagulant activities of high and low molecular weight heparin fractions. Br J Haematol 1979 0.91
13 Electron crystallography of human blood coagulation factor VIII bound to phospholipid monolayers. J Biol Chem 1999 0.87
14 Inhibition of tissue factor-dependent and -independent coagulation by cell surface expression of novel anticoagulant fusion proteins. Transplantation 1999 0.84
15 Regulated inhibition of coagulation by porcine endothelial cells expressing P-selectin-tagged hirudin and tissue factor pathway inhibitor fusion proteins. Transplantation 1999 0.84
16 Molecular analysis of the genotype-phenotype relationship in factor VII deficiency. Hum Genet 2000 0.83
17 Factor VII deficiency and the FVII mutation database. Hum Mutat 2001 0.81
18 Factor VIII degradation products in heated concentrates. Lancet 1986 0.81
19 Binding to phospholipid protects factor VIII from inactivation by human antibodies. J Lab Clin Med 1983 0.81
20 The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII. Blood 1998 0.81
21 Human tissue factor pathway inhibitor fused to CD4 binds both FXa and TF/FVIIa at the cell surface. Thromb Haemost 1997 0.80
22 Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M. Thromb Haemost 1996 0.78
23 Factor VIII concentrates contain factor VIII procoagulant antigen bound to phospholipid. Br J Haematol 1986 0.78
24 Expression of hirudin fusion proteins in mammalian cells: a strategy for prevention of intravascular thrombosis. Circulation 1998 0.77
25 The solution structure of human coagulation factor VIIa in its complex with tissue factor is similar to free factor VIIa: a study of a heterodimeric receptor-ligand complex by X-ray and neutron scattering and computational modeling. Biochemistry 1998 0.77
26 The effect of Ca2+, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides. Biochem J 1987 0.77
27 Inhibitor development and activated factor VIII in concentrates. Thromb Haemost 1993 0.77
28 Human thrombin and FXa mediate porcine endothelial cell activation; modulation by expression of TFPI-CD4 and hirudin-CD4 fusion proteins. Xenotransplantation 2001 0.76
29 Factor VIIa and the extracellular domains of human tissue factor form a compact complex: a study by X-ray and neutron solution scattering. FEBS Lett 1995 0.76
30 Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family. Br J Haematol 2000 0.76
31 Detection of missense mutations by single-strand conformational polymorphism (SSCP) analysis in five dysfunctional variants of coagulation factor VII. Hum Mol Genet 1993 0.75
32 Effect of phospholipid on factor VIII inactivation. Prog Clin Biol Res 1984 0.75
33 In vivo studies of activated porcine factor VIII. Thromb Haemost 1996 0.75
34 Regulated endothelial cell expression of novel anticoagulants: a strategy for the prevention and therapy of intravascular thrombosis. Transplant Proc 2000 0.75
35 Factor VIII inhibitor bypassing activity: a suggested mechanism of action. Thromb Res 1981 0.75
36 Assay of factor VIII concentrates: comparison of the chromogenic and two-stage clotting assays. Thromb Res 1986 0.75
37 Crystallization and preliminary X-ray analysis of active site-inhibited human coagulation factor VIIa (des-Gla). J Struct Biol 1999 0.75
38 Fractionation of human antibody to factor VIII:C: and IRMA for phospholipid binding sites on factor VIII C:Ag. Br J Haematol 1984 0.75
39 Variable inactivation of human factor VIII from different sources by human factor VIII inhibitors. Br J Haematol 1991 0.75
40 Homology modelling of the catalytic domain of early mammalian protein C: evolution of structural features. Hum Genet 1997 0.75
41 Potency of high purity factor VIII concentrates. Lancet 1990 0.75
42 Structural determination of lipid-bound human blood coagulation factor IX. Biochim Biophys Acta 1998 0.75
43 Absorption of factor VIII by aluminium hydroxide. Haemostasis 1979 0.75
44 Diagnostic importance of the two-stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His1954-->Leu substitution in the factor VIII A3 domain. Br J Haematol 1999 0.75
45 Aluminium hydroxide absorption of factor VIII procoagulant antigen from plasma and factor VIII concentrate. Thromb Res 1982 0.75
46 Stable recombinant expression and characterization of the two haemophilic factor VIII variants C329S (CRM(-)) and G1948D (CRM(r)). Br J Haematol 2001 0.75
47 Factor VIII-related activities in therapeutic concentrates. J Lab Clin Med 1981 0.75
48 Overcoming factor VIII inhibitors: a possible new approach. Scand J Haematol Suppl 1984 0.75